{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:51:29Z","timestamp":1758819089375,"version":"3.44.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"am","delay-in-days":390,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.bulcan.2019.10.004","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T18:35:02Z","timestamp":1576521302000},"page":"157-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u00c9tude r\u00e9trospective\u00a0: chirurgie d\u2019intervalle tardive post chimioth\u00e9rapie versus apr\u00e8s 3\u20134\u00a0cures dans le cadre de la prise en charge d\u2019un cancer de l\u2019ovaire localement avanc\u00e9 non op\u00e9rable d\u2019embl\u00e9e"],"prefix":"10.1016","volume":"107","author":[{"given":"Quiterie","family":"de Fr\u00e9minville","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idlir","family":"Licaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Sebastien","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Hamel-Senecal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Emmanuel","family":"Brachet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie","family":"Coquan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Leconte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Classe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2019.10.004_bib0325","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0330","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0335","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","article-title":"FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology","volume":"70","author":"Benedet","year":"2000","journal-title":"Int J Gynaecol Obstet"},{"issue":"8","key":"10.1016\/j.bulcan.2019.10.004_bib0340","first-page":"766","article-title":"Ovarian cancer. Clinical practice guidelines in oncology","volume":"6","author":"Morgan","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.bulcan.2019.10.004_bib0345","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"Natl Cancer Inst Monogr"},{"issue":"4","key":"10.1016\/j.bulcan.2019.10.004_bib0350","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0355","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/gyno.1998.4955","article-title":"Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study","volume":"69","author":"Eisenkop","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2019.10.004_bib0360","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1006\/gyno.2001.6328","article-title":"Identification of prognostic factors in advanced epithelial ovarian carcinoma","volume":"82","author":"Chi","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.004_bib0365","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","article-title":"Aggressive surgical effort and improved survival in advanced-stage ovarian cancer","volume":"107","author":"Aletti","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"24","key":"10.1016\/j.bulcan.2019.10.004_bib0370","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2019.10.004_bib0375","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/IGC.0b013e31823de6ae","article-title":"Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA\u2013IV: analysis of the OVCAD data","volume":"22","author":"Polterauer","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2019.10.004_bib0380","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2019.10.004_bib0385","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2019.10.004_bib0390","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/j.1471-0528.1999.tb08137.x","article-title":"Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866\u00a0patients","volume":"106","author":"Junor","year":"1999","journal-title":"Br J Obstet Gynaecol"},{"issue":"Suppl 1","key":"10.1016\/j.bulcan.2019.10.004_bib0395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/ijgc-00009577-200602001-00002","article-title":"Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals","volume":"16","author":"Paulsen","year":"2006","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0400","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ygyno.2008.09.036","article-title":"Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review","volume":"112","author":"du Bois","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2019.10.004_bib0405","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.ajog.2005.06.074","article-title":"Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients","volume":"193","author":"Sharma","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.004_bib0410","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ygyno.2007.05.032","article-title":"A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model","volume":"107","author":"Aletti","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0415","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ygyno.2007.10.001","article-title":"The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer","volume":"108","author":"Zivanovic","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2019.10.004_bib0420","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2009.08.004","article-title":"Clinical audit in gynecological cancer surgery: development of a risk scoring system to predict adverse events","volume":"115","author":"Kondalsamy-Chennakesavan","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.004_bib0425","first-page":"9","article-title":"Extensive cytoreductive surgery in advanced ovarian carcinoma","volume":"18","author":"Michel","year":"1997","journal-title":"Eur J Gynaecol Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.004_bib0430","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2010.09.010","article-title":"Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment","volume":"120","author":"Aletti","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2019.10.004_bib0435","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/030089168907500620","article-title":"The role of induction chemotherapy in inoperable ovarian cancer","volume":"75","author":"Donadio","year":"1989","journal-title":"Tumori"},{"issue":"4","key":"10.1016\/j.bulcan.2019.10.004_bib0440","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/1120009X.1990.11739028","article-title":"Advanced epithelial ovarian cancer: no difference in survival rate between exploratory laparotomy and inadequate debulking surgery as treatment approach before chemotherapy","volume":"2","author":"Tummarello","year":"1990","journal-title":"J Chemother Florence Italy"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0445","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0090-8258(91)90335-3","article-title":"Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer","volume":"42","author":"Jacob","year":"1991","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2019.10.004_bib0450","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0936-6555(05)80227-4","article-title":"Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma","volume":"5","author":"Lim","year":"1993","journal-title":"Clin Oncol R Coll Radiol G B"},{"issue":"3","key":"10.1016\/j.bulcan.2019.10.004_bib0455","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1006\/gyno.1998.5213","article-title":"Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285\u00a0patients","volume":"71","author":"Vergote","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2019.10.004_bib0460","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1002\/1097-0142(20010615)91:12<2329::AID-CNCR1265>3.0.CO;2-U","article-title":"Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study","volume":"91","author":"Ansquer","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2019.10.004_bib0465","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1525-1438.2001.01064.x","article-title":"Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma","volume":"11","author":"Lu","year":"2001","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"10.1016\/j.bulcan.2019.10.004_bib0470","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1002\/1097-0142(20011115)92:10<2585::AID-CNCR1611>3.0.CO;2-#","article-title":"Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma","volume":"92","author":"Kuhn","year":"2001","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2019.10.004_bib0475","first-page":"405","article-title":"Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study","volume":"23","author":"Vrscaj","year":"2002","journal-title":"Eur J Gynaecol Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2019.10.004_bib0480","first-page":"185","article-title":"Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer","volume":"87","author":"Ushijima","year":"2002","journal-title":"Int Surg"},{"issue":"4","key":"10.1016\/j.bulcan.2019.10.004_bib0485","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000074644","article-title":"Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients","volume":"65","author":"Fanfani","year":"2003","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.004_bib0490","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/gyno.2002.6849","article-title":"Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study","volume":"88","author":"Chan","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.004_bib0495","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/annonc\/mdg003","article-title":"Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study","volume":"14","author":"Morice","year":"2003","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.004_bib0500","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0090-8258(03)00249-X","article-title":"Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer","volume":"90","author":"Mazzeo","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2019.10.004_bib0505","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/ijgc-00009577-200309000-00003","article-title":"Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors","volume":"13","author":"Shibata","year":"2003","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2019.10.004_bib0510","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jamcollsurg.2003.06.004","article-title":"Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer","volume":"197","author":"Morice","year":"2003","journal-title":"J Am Coll Surg"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0515","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/ijgc-00009577-200503000-00005","article-title":"Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study","volume":"15","author":"Loizzi","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bulcan.2019.10.004_bib0520","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1477-7819-3-57","article-title":"Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma","volume":"3","author":"Hegazy","year":"2005","journal-title":"World J Surg Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2019.10.004_bib0525","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ijgc-00009577-200509000-00009","article-title":"Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer","volume":"15","author":"Le","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"30","key":"10.1016\/j.bulcan.2019.10.004_bib0530","doi-asserted-by":"crossref","first-page":"7445","DOI":"10.1200\/JCO.2005.06.965","article-title":"Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer","volume":"23","author":"Avril","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.004_bib0535","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1447-0756.2006.00359.x","article-title":"Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery","volume":"32","author":"Lee","year":"2006","journal-title":"J Obstet Gynaecol Res"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0540","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ajog.2006.03.075","article-title":"Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III\/IV epithelial ovarian cancer","volume":"195","author":"Everett","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.004_bib0545","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2006.11.025","article-title":"Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease","volume":"105","author":"Hou","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2019.10.004_bib0550","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","article-title":"Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0555","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ygyno.2006.11.002","article-title":"Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction","volume":"104","author":"Bristow","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2019.10.004_bib0560","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1245\/s10434-009-0558-6","article-title":"Does Neoadjuvant Chemotherapy Increase Optimal Cytoreduction Rate in Advanced Ovarian Cancer? Meta-Analysis of 21\u00a0Studies","volume":"16","author":"Kang","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2019.10.004_bib0565","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"9990","key":"10.1016\/j.bulcan.2019.10.004_bib0570","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0575","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2014.09.002","article-title":"Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer","volume":"135","author":"Colombo","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0580","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00404-016-4256-x","article-title":"The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc\u2013IV high-grade serous ovarian cancer","volume":"295","author":"Xu","year":"2017","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"10.1016\/j.bulcan.2019.10.004_bib0585","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ejso.2018.01.097","article-title":"Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer","volume":"44","author":"Phillips","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2019.10.004_bib0590","first-page":"423","article-title":"Analysis of the treatment of ovarian cancer patients with neo-adjuvant chemotherapy-preliminary results","volume":"26","author":"Bidzi\u0144ski","year":"2005","journal-title":"Eur J Gynaecol Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0595","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejogrb.2011.07.014","article-title":"Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined?","volume":"159","author":"Stoeckle","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0600","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ygyno.2013.12.002","article-title":"Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness","volume":"132","author":"da Costa Miranda","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.10.004_bib0605","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1245\/s10434-013-3278-x","article-title":"Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum\/taxane-based chemotherapy and late interval debulking surgery","volume":"21","author":"Stoeckle","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2019.10.004_bib0610","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000449203","article-title":"Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?","volume":"91","author":"Akladios","year":"2016","journal-title":"Oncology"},{"issue":"9","key":"10.1016\/j.bulcan.2019.10.004_bib0615","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1097\/IGC.0000000000001108","article-title":"The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC\u2013IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study","volume":"27","author":"Bogani","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2019.10.004_bib0620","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1245\/s10434-016-5704-3","article-title":"Neoadjuvant Chemotherapy Increases R0\u00a0Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer","volume":"24","author":"Medina-Franco","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"11\u201312","key":"10.1016\/j.bulcan.2019.10.004_bib0625","first-page":"1727","article-title":"A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate","volume":"63","author":"Goldie","year":"1979","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.004_bib0630","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2013.01.009","article-title":"Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma","volume":"129","author":"Rauh-Hain","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2019.10.004_bib0635","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00280-004-0993-9","article-title":"Neoadjuvant chemotherapy for epithelial ovarian cancer-role of apoptosis","volume":"56","author":"Dutta","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.bulcan.2019.10.004_bib0320","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1701-2163(16)34052-X","article-title":"Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer?","volume":"31","author":"Le","year":"2009","journal-title":"J Obstet Gynaecol Can"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455119304060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455119304060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:31:58Z","timestamp":1757791918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455119304060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0007455119304060"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.10.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9tude r\u00e9trospective\u00a0: chirurgie d\u2019intervalle tardive post chimioth\u00e9rapie versus apr\u00e8s 3\u20134\u00a0cures dans le cadre de la prise en charge d\u2019un cancer de l\u2019ovaire localement avanc\u00e9 non op\u00e9rable d\u2019embl\u00e9e","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}